English

Abstract

BACKGROUND: Pneumoperitoneum required for laparoscopic surgeries results in various pathophysiologic changes in the body, especially in the cardiovascular system. Moxonidine is a selective Imidazoline I1-receptor agonist with an I1:α2 affinity ratio of 40:1 to 70:1. Through an action in the Rostral Ventrolateral Medulla (RVLM), where the I1 receptors are situated, it reduces sympathetic outflow and lowers peripheral vascular resistance. BP reduction is not accompanied by any significant change in heart rate or cardiac output. AIMS AND OBJECTIVES: The aim of our study was to evaluate effect of orally administered Moxonidine in attenuating the hemodynamic responses that occur during laparoscopic cholecystectomy. MATERIALS AND METHODS: 50 adult ASA I and II patients scheduled for elective laparoscopic cholecystectomy were selected for this prospective randomized double blinded comparative study. They were randomly allocated to two groups; Moxonidine group and Placebo group. Moxonidine group received oral Moxonidine 0.3 mg at 8 PM the day before surgery and at 8 AM on the day of surgery. Placebo group received a placebo at the same timing as that of the Moxonidine group. RESULTS: When vital parameters were compared significant rise in heart rate, systolic, diastolic and mean blood pressure was noted in the Placebo group following pneumoperitoneum, where as in Moxonidine group the rise was not more than 20% of baseline. CONCLUSION: In conclusion, Moxonidine when administered preoperatively provides perioperative hemodynamic stability in ASA I and II patients undergoing laparoscopic cholecystectomy. It's other benefits such as absence of reflex tachycardia, preservation of hepatic and